Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
S. Bozzini (Pavia, Italy), G. Zanframundo (Pavia, Italy), V. Codullo (Pavia, Italy), V. Frangipane (Pavia, Italy), L. Pandolfi (Pavia, Italy), S. Lettieri (Pavia, Italy), B. Atienza-Mateo (Santander, Spain), S. Remuzgo Martinez (Santander, Spain), C. Montecucco (Pavia, Italy), M. Gonzalez-Gay (Santander, Spain), L. Cavagna (Pavia, Italy), F. Meloni (Pavia, Italy). Plasma derived-exosome microRNAs in Idiopathic Pulmonary Fibrosis of Anti-synthetase syndrome Disease patients. 726

Member's Comments

No comment yet.

Related content which might interest you: Impact of depression on patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – Best clinical practice for the management of chronic lung diseases Year: 2017 Association between Pulmonary Infections and the Prognosis in Patients with Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Platelet activation indices in patients with Idiopathic Pulmonary Fibrosis Source: International Congress 2014 – ILDs 5 Year: 2014 Treatment of Idiopathic Pulmonary Fibrosis Source: Guideline 2015 Year: 2015 Tele-rehabilitation program in Idiopathic Pulmonary Fibrosis Source: International Congress 2019 – M-health/e-health I Year: 2019 IPF - Idiopathic Pulmonary Fibrosis Source: Breathe, 15 (2) 153; 10.1183/20734735.ELF152 Year: 2019 Prevalence and Characteristics of Patients Receiving Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry Source: Eur Respir J , 49 (2) 1601592; DOI: 10.1183/13993003.01592-2016 Year: 2017 MMP7-degraded elastin is elevated in serum of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Basic and translational research in lung cancer and non-neoplastic pulmonary diseases Year: 2014 Clinical Features and Prognosis of Acute exacerbation of Connective Tissue Diseases Associated Pulmonary Fibrosis------ Comparision with Idiopathic Pulmonary Fibrosis Source: International Congress 2017 – The spectrum of CTDs: from pathogenesis to treatment Year: 2017 Evaluation of Dyspnea Questionnaires in Patients with Idiopathic Pulmonary Fibrosis (IPF). Source: International Congress 2018 – Consequences of idiopathic interstitial pneumonias Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2018 Idiopathic Pulmonary Fibrosis (IPF) Source: ERS Courses: Interstitial Lung Diseases Year: 2019 Clinical Correlates of Physical Activity in Idiopathic Pulmonary Fibrosis (IPF) Source: International Congress 2019 – Pulmonary rehabilitation for non-obstructive lung diseases Year: 2019 Risk Factor for Chronic Obstructive Pulmonary Disease in Never-Smoker Patients with Non-Cystic Fibrosis Bronchiectasis Source: International Congress 2019 – Bronchiectasis Year: 2019 Angiopoietin-2 gene polymorphism as prognostic factor in caucasians with idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 1 Year: 2014 Is Pulmonary Rehabilitation A Savior In Idiopathic Pulmonary Fibrosis? Source: Virtual Congress 2020 – News on diagnosis and therapy of idiopathic pulmonary fibrosis Year: 2020 Epidemiology of Idiopathic Pulmonary Fibrosis in Australia Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 Serum ST2 in Idiopathic Pulmonary Fibrosis (IPF): a possible new biomarker of disease? Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020